Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT07263074
Status
Recruiting
Apply to this trial

Conditions

  • Myeloid Malignancy

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CHORDS — OTHER
    The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).

Study Details

This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).

Key Dates

Start date
Jan 15, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Intervention (CHORDS)
    The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).
  • No Intervention: Usual Care
    Patients randomized to the usual care arm will receive standard of care. Patients (and their caregivers when available) randomized to usual care will not participate in CHORDS. Patients and caregivers will complete baseline (T1) and post-alloHCT office visit (T3, T4, T5) assessments.

Primary Outcome Measure

Percentage of Participants Retained (Feasibility - Retention Rate) [ Time Frame: From enrollment (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642
Rachel Rodenbach
[email protected]
585-275-5830
Rachel Rodenbach (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, NY

By research site
University of Rochester· Rochester, NY

Related Studies